603127 昭衍新藥
按盤價 
17.680 -1.160 (-6.157%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 1,335,156 | -15.87% | 2,376,487 | 2,267,971 | 1,516,680 | 1,075,905 | |
| 減：營業總成本 | 1,227,734 | 11.12% | 1,622,010 | 1,418,766 | 1,086,978 | 804,306 | |
| 其中:營業成本 | 968,252 | 8.49% | 1,363,701 | 1,181,660 | 777,558 | 523,092 | |
| 財務費用 | (74,636) | -37.05% | (151,091) | (154,682) | (19,156) | 2,477 | |
| 資產減值損失 | (25,480) | 370.21% | (31,232) | (2,792) | (1,331) | (1,510) | |
| 公允價值變動收益 | (190,401) | 75.46% | (245,642) | 349,567 | 157,777 | 58,946 | |
| 投資收益 | 31,620 | 342.76% | 9,628 | 13,022 | 17,000 | 1,524 | |
| 其中：對聯營企業和合營企業的投資收益 | 15,471 | -705.98% | (3,069) | (2,691) | (426) | -- | |
| 營業利潤 | (69,661) | -117.77% | 507,096 | 1,225,639 | 642,889 | 361,118 | |
| 利潤總額 | (69,892) | -117.83% | 506,950 | 1,240,002 | 642,004 | 360,572 | |
| 減：所得稅費用 | 4,352 | -93.39% | 115,398 | 166,802 | 85,587 | 46,944 | |
| 淨利潤 | (74,244) | -122.76% | 391,553 | 1,073,200 | 556,416 | 313,628 | |
| 減：非控股權益 | (3,937) | 180.94% | (5,440) | (1,057) | (1,043) | (1,386) | |
| 股東淨利潤 | (70,307) | -121.46% | 396,993 | 1,074,257 | 557,460 | 315,014 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.090 | -120.45% | 0.530 | 1.440 | 1.080 | 1.000 | |
| 每股派息 (元) * | -- | -- | 0.160 | 0.400 | 0.360 | 0.350 | |
| 每股淨資產 (元) * | 10.677 | -2.76% | 11.040 | 15.277 | 18.720 | 5.390 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 22/11/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
